ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...
ALX Oncology is laying off 30% of its staff, mainly in preclinical research, to redirect money toward clinical trials, ...
ALX Oncology (ALXO) will highlight progress across its clinical pipeline, including continued advancement of investigational CD47-blocker evorpacept and planned entry into the clinic of its novel ...
ALX Oncology announced promising results from the ASPEN-06 Phase 2 clinical trial of its CD47-blocker, evorpacept, at the 2025 ASCO Gastrointestinal Cancers Symposium. This investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results